Daily Roundup

TTX.ASX VBC.ASX TLX.ASX BGD.ASX VR1.ASX

Tetratherix Launches New Precision Medicine Franchise

Tetratherix Limited (ASX:TTX) is expanding its horizons with the launch of a new precision medicine franchise leveraging its innovative Tetramatrix platform. This move further showcases the versatility of the Tetramatrix technology, which already powers the company's bone regeneration, tissue spacing, and tissue healing franchises.

The precision medicine franchise will be immediately revenue-generating, thanks to an exclusive research and development (R&D) agreement with the US consumer health group Superpower Health Inc. Under the deal, Superpower will pay Tetratherix a cool $3 million per year for up to a decade, licensing the Tetramatrix platform polymer (branded as STEPP) for nasal delivery of longevity and metabolic compounds like GLP-1, peptides, and hormones in the US market.

Tetratherix's CEO is thrilled about the partnership, noting that it will allow the company to gather real-world evidence on health outcomes and consumer preferences, positioning Tetramatrix as the delivery mechanism for a new era of preventative healthcare. And the good news doesn't stop there - the company remains on track to receive two FDA approvals in its bone regeneration franchise by mid-2026.

Verbrec Appoints Industry Veteran as Managing Director

Over at Verbrec Limited (ASX:VBC), the board has made a savvy move, appointing Mark Read as the company's new Managing Director. Mark has been an integral part of Verbrec's turnaround journey and current growth trajectory since taking on the role of CEO in 2023, and his 30+ years of industry experience make him the perfect fit for the top job.

To ensure continuity, the board has extended Mark's notice period from 6 months to a full year. In a note to shareholders, Mark expressed his gratitude for the opportunity and reiterated his commitment to working collaboratively with the board to drive value for Verbrec's investors, elevate the company's brand, and enable a sustainable future for its clients.

Telix Resubmits Brain Cancer Imaging Drug to FDA

Telix Pharmaceuticals Limited (ASX:TLX) has taken a significant step forward, resubmitting its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TLX101-Px (Pixclara®), an investigational PET imaging agent for brain cancer.

The resubmission includes additional data requested by the FDA to address a previous Complete Response Letter. Given TLX101-Px's potential to address a critical unmet medical need, the drug has been granted both Orphan Drug and Fast Track designations by the regulatory body.

If approved, TLX101-Px would be the first FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging in the United States, providing a valuable new tool for clinicians.

Barton Gold Accelerates Tunkillia Gold Project Development

Barton Gold Holdings Limited (ASX:BGD) is wasting no time in unlocking the value of its Tunkillia Gold Project in South Australia, kicking off a ~30,000-meter reverse circulation drilling program to further upgrade the project's economics.

The 'Phase 2' drilling follows successful 'Phase 1' results, which returned broad, high-grade intersections and supported rapid payback in the early 'Starter pit'. Barton is now aiming to convert all optimised open pit mineralisation to JORC 'Measured' and 'Indicated' categories, accelerating financing and development.

The company's May 2025 Optimised Scoping Study painted a compelling picture, with the initial S1 and S2 pits modelled to produce over 1.2 million ounces of gold and silver in the first 27 months alone. And at current prices, Barton estimates Tunkillia could generate over $1 billion in operating profit in its first year of production.

Vection Secures $4M in New AI Orders

Vection Technologies Ltd (ASX:VR1) is riding a wave of momentum, securing approximately $4 million in new orders for its proprietary Algho AI platform since the start of February 2026.

These orders span 10 industry verticals, including rail, healthcare, utilities, and more, reinforcing the versatility of Vection's AI solutions and broadening the company's revenue base. High-profile clients include the primary national passenger rail operator in Italy, a global leader in eye health, and one of the main water utilities serving Tuscany.

This result follows Vection's record H1 FY26 financial performance, with revenue up 34% and gross margins climbing to 56%. The new AI orders represent 87% of the total AI revenue booked in the first half, underscoring the growing scalability of the Algho platform.